/Investor DB

LionBird — 2025 Investments

4 investments dated 2025 · listed companies and verified rows first · show all

ectonecton.ioFeb 2025

ecton develops financial technology focused on healthcare payments and patient loyalty, aiming to help patients manage medical costs and improve their financial health.

AI & Machine LearningDigital HealthFintechHealthtech

Itamar Perlov(Founder)in

Co-investorsClocktower VenturesGeneral CatalystUpWest

PhaseVphasevtrials.cominSeries A · May 2025 · $50M

PhaseV provides AI/ML-driven software for designing and optimizing clinical trials, including trial simulation, adaptive design, patient subgroup identification, and early endpoint detection.

AI & Machine LearningBiotechDigital HealthCambridge, US

Elad Berkman(Founder)in

Co-investorsAccelViola VenturesExorExor VenturesInsight Partners

Rhinorhino.aiinMay 2025 · $15M

Rhino builds a system of record for enterprise business logic, rules, and decisions that are typically scattered across legacy systems and processes.

AI & Machine LearningData & InfrastructureDeveloper ToolsEnterprise SoftwareAlexandria, US

Adam Branch(Executive Officer, Director, Promoter)in

BoardHarrison Touati(Director)Jon Galitzer(Director)

Co-investorsKoch Disruptive TechnologiesMitsui Global InvestmentAlleyCorpArkin Digital HealthGaingelsJLL Spark Global Ventures+3 more

Rhino Federated Computingrhinofcp.cominMay 2025

Rhino Federated Computing provides enterprise software infrastructure enabling organizations to run AI, analytics, and data workflows across distributed data environments while preserving privacy and security.

AI & Machine LearningData & InfrastructureEnterprise SoftwareBoston, US

Ittai Dayan(Dr.)inYuval Baror(Founder)inChristopher Laws(Executive Officer)

BoardEdward Michael(Director)inIvneet Bhullar(Director)in

Co-investorsAlleyCorpE12 Venture Capital, LlcFusionMana VenturesMitsui Global InvestmentQiming Venture Partners USA+6 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.